Adagene Inc. ADAG
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +27.51%
- 1 year
- +41.76%
- Market cap
- 161.82M
- Revenue (ttm)
- 815.75K
- EPS (ttm)
- -0.38
- Shares out
- 44.27M
- Forward P/E
- -2.81
- YTD return
- +27.51%
- 1-year return
- +41.76%
- Volume
- 114.83K
- Avg volume
- 281.54K
- Open
- 2.49
- Previous close
- 2.35
- Day's range
- 2.34 – 2.52
- 52-week range
- 1.30 – 4.85
- Beta
- 0.58
- Price target
- 8.03 (+233.1%)
- Earnings date
- Apr 2, 2024
YTD +0.64 (+34.78%)
Key statistics
- Enterprise value
- 38.56M
- PEG ratio
- 0.00
- Price / sales
- 105.28
- Price / book
- 1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.92M
- Total cash
- 95.67M
- Total debt
- 20.79M
- Return on equity
- -45.70%
- Short % of float
- 0.10%
- 50-day average
- 2.44
- 200-day average
- 2.59
Analyst view
- Target (low)
- 3.50
- Target (mean)
- 8.03
- Target (high)
- 18.81
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Apr 2, 2024
Expected Apr 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 2, 2024 | Dec 1, 2023 | -0.42 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -0.36 | — | — | — |
| Mar 30, 2022 | Dec 1, 2021 | -1.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 1, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 21, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- adagene.com
News
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer 
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer 
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference 
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer 
Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright 
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts 
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts 
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference 
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology 
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Your note
Sign in to keep a note on ADAG — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wuxi Apptec Co., Ltd. | 9.00% | 3,982,902 | 7.73M | Sep 29, 2024 |
| FIL LTD | 8.13% | 3,600,396 | 6.98M | Sep 29, 2024 |
| HSG Holding Ltd. | 3.03% | 1,343,364 | 2.61M | Sep 29, 2024 |
| FMR, LLC | 2.91% | 1,290,400 | 2.50M | Sep 29, 2024 |
| General Atlantic, L.P. | 0.60% | 264,000 | 512.16K | Sep 29, 2024 |
| Exome Asset Management LLC | 0.59% | 262,625 | 509.49K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 10,309 | 20.00K | Oct 30, 2024 |